
feb pm et
summari compani lead wholesal distributor pharmaceut medical/surg
suppli relat product broad rang health care custom
price-to-earnings oper ep
servic think good growth
prospect contract drug make drug
dispens system howev also see intens
competit drug distribut market futur
drugmaker-distributor contract negoti could
less favor distributor think
fiscal year end jun ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
slower growth experienc fy
revenu hurt mid-singl digit deflationari
gener drug price fewer new gener
drug launch expect brand drug
manufactur price increas
despit new custom win medic
segment see high teen sale growth
acquisit medic recoveri
expect ebitda margin flat
off-set expect synergi improv
sourc suppli chain save
acquisit patient recoveri
busi gener drug purchas
benefit red oak drug purchas joint
ventur
expect per share accret
acquisit busi fy
net higher interest expens
reflect high debt need fund deal
follow benefit lower tax
rate share repurchas forecast fy
oper ep oper ep
fy one-tim item
period
compani acquir patient deep
vein thrombosi nutrit insuffici
busi
billion cash juli view
deal favor help diversifi
busi expand complementari
expect deal accret ep
fy howev optim
mitig near-term valuat ep
growth pressur see advers
risk recommend target price
includ intensifi competit loss
major account consolid trend
 retail pharmaci industri reduc
target price reflect
forward price-to-earnings near low end
five-year trade rang
appli fy ep estim
think discount valuat warrant given
benefit see recent acquisit
strength compani medic
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview rank one nation largest wholesal
pharmaceut medic product august compani spun sharehold
stock carefus corp cfn compani form cardin previou devic busi design
prevent hospit medic error infect
segment revenu fy jun distribut pharmaceut relat
health care product independ chain drug store hospit altern care center
supermarket mass merchandis pharmaci compani also provid pharmaceut
repackag distribut retail mail order custom cardin also offer third-parti logist
support servic distribut therapeut plasma hospit clinic provid locat
compani manufactur market gener pharmaceut product sale hospit clinic
pharmaci unit kingdom also specialti pharmaci provid prescript
fulfil clinic care servic directli individu patient requir highli intens therapi
cardin oper world largest network nuclear pharmaci expand positron
emiss tomographi pet agent manufactur capabl support new drug develop
futur person medicin unit prepar deliv radio-pharmaceut use nuclear
imag procedur hospit clinic addit hospit across
outsourc manag inpati pharmaci cardin
medic segment revenu distribut medical-surg product ambulatori care center
physician offic clinic laboratori hospit across canada unit also produc
glove gown surgic drape scrub fluid manag product addit segment conduct
surgic procedur kit oper assembl necessari single-us surgic product
apparel specif procedur one kit allow clinician focu patient
corpor strategi think execut well core busi strategi
nation chain side independ pharmaci side drug distribut busi compani
also increas gener penetr rate distributor usual deriv higher margin gener
brand sale octob complet acquisit cordi manufactur
distributor intervent cardiolog devic endovascular solut billion cash juli
compani acquir harvard drug distributor gener drug counter healthcar
relat product billion net cash acquir march acquir assuram lead
distributor home health care product billion also significantli expand exposur
higher-margin independ pharmaci sector decemb acquisit kinray new
york drug distributor billion cash novemb cardin broaden base oversea
drug distribut acquisit yong yu lead distributor china million
june cardin creat gener sourc suppli chain joint ventur jv
name red oak sourc llc commit sourc gener drug
jv part creation jv requir make quarterli million payment
commenc octob
corpor govern gener favor view compani corpor govern
board director control larg major independ outsid compens
committe compos sole independ outsid howev concern ceo also
hold posit chairman
financi trend total revenu experienc five-year compound annual growth rate
reflect new custom win partial off-set loss walgreen
busi fy total oper cash flow billion fy billion fy
june cardin total cash posit billion billion june
long-term debt end june total billion billion june
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
cost control divestitur
under-perform unit profit
stock benefit acquisit
june health
distributor increas vs
increas composit
sub-industri index
declin versu gain
fundament outlook health care
distributor sub-industri next
month posit outlook base
mainli healthi profit growth see
drug suppli segment gener
compris busi
three larg drug distributor make
bulk market-cap weight
distributor benefit new gener
result patent expir mani
large-sel brand drug view
gener import drug distributor
carri wider margin brand
product howev note drug price inflat
like moder
acquisit strateg partner
sector also increas
cardin
drug-sourc contract
longer term expect larg
distributor realiz high-single-digit
annual ep gain benefit gener drug
penetr age popul drug price
inflat addit expect
million addit american eventu
cover health insur afford
act therefor better abl
afford pharmaceut howev
expect robust growth distributor top line
next year owe patent loss
sever blockbust drug merger among
major drugmak might put pressur
fee distributor receiv
supplier also new health care
legisl expect neg
impact health care coverag long-term
coverag level may neg impact
contributor margin expans
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
cah averag fy jun ep estim
believ discount warrant given unfavor drug price
trend set fy ep estim jun-q adjust ep vs
estim due lower expect tax see fy
ep hurt cost relat launch new program
pharmaceut segment drive custom growth local commun educ
prevent address opiod crisi tax plan /j agnes
et cfra keep hold opinion share cardin
keep target price price-to-earnings fy
jun ep estim averag see
valuat hurt unfavor drug price despit medic segment strength
mar-q ep vs estim lower
expect tax pharmaceut distribut hurt gener drug price
pressur partial off-set improv purchas see jun-q comparison
eas lap custom loss fy medic result benefit
improv product mix increas distribut servic /j agnes
et cfra maintain hold opinion share cardin
inc cut target price-to-earnings
averag fy jun ep estim
cut fy ep estim
agre acquir patient recoveri busi
billion cash view deal favor diversifi
busi expand complementari medic product offer
expect fy ep accret reduc fy fy
outlook reflect greater expect deflationari gener drug price
et capit iq keep hold opinion share
inc keep target price
price-to-earnings averag fy jun
ep estim see valuat ep restrict
less favor drug price despit strength specialti medic
segment cut fy ep estim dec-q ep
vs estim margin narrow less
expect deflationari gener drug price loss larg custom
mostli off-set improv purchas accret acquisit
analyst research note compani news
rais target price-to-earnings
near low end rang fy jun ep estim
think discount warrant given low drug price
inflat despit benefit see recent acquisit strength
medic specialti busi increas fy ep estim
see tax reform increas ep fy
fy dec-q ep vs estim
result benefit strong specialti demand improv purchas /joseph
elect akhil johri execut vice presid chief
financi offic unit technolog board
effect feb addit johri name board audit
committe johri addit board board
consist thirteen director eleven independ johri return
unit technolog serv chief offic pall
donald casey jr chief execut offic medic segment notifi
inc leav compani effect februari
jon giacomin chief execut offic segment
lower target price-to-earnings
near low end rang fy jun ep estim
think discount warrant given low drug price
inflat despit benefit see recent acquisit strength
medic specialti busi decreas fy ep estim
sep-q ep vs estim
result hurt loss mail order custom may less
favor price despit strong specialti demand improv purchas
announc name mike kaufmann current chief
financi offic serv compani next chief execut offic
join board director effect jan kaufmann succeed
georg barrett chairman chief execut offic sinc
continu serv execut chairman board
director annual meet sharehold novemb
time gregori kenni lead independ director assum
role non-execut chairman kaufmann veteran cardin
respons compani financi activ
addit overse global sourc medic
segment member senior execut team kaufmann
play import role develop execut compani strategi
also instrument key strateg initi includ compani
joint ventur red oak sourc serv board
director creation fuse technolog innov
center previous held senior commerci oper leadership
posit across medic busi addit
part success plan jorg gomez succeed mike kaufmann
chief financi offic gomez current serv senior
vice presid chief financi offic medic segment
previous serv chief financi offic
pharmaceut segment well role compani treasur
control prior join year ago gomez spent close
year serv varieti financi
lower target price price-to-earnings
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
